Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Inclusion Criteria: * Have relapsed or refractory MM treated with at least 1 prior regimen. Prior therapy with bortezomib is allowed if there was previously at least a minimal response (MR). * Have measurable disease as defined by one or more of the following: * serum M-protein concentration ≥ 1 g/dL (10 g/L) * urine monoclonal light chain concentration ≥ 200 mg/24 hours as determined by urine protein electrophoresis * involved serum free light chain (SFLC) concentration ≥ 10 mg/dL (100 mg/L) and an abnormal SFLC ratio * Have adequate organ function including: * Absolute neutrophil count (ANC) ≥ 1000/microliter * Platelet (PLT) count ≥ 75,000/microliter * Hemoglobin (Hgb) ≥ 8.0 g/dL * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (if total is elevated check direct and, if normal, participant is eligible) * Aspartate transaminase (AST) and alanine aminotransferase (ALT) are ≤ 3 x ULN * Serum creatinine ≤ 3.0 mg/dL. * Have an Eastern Cooperative Oncology Group performance status (ECOG PS) score of ≤ 2. * Have discontinued all previous therapies for cancer, including chemotherapy, surgery, and radiotherapy for at least 2 weeks (6 weeks for mitomycin-C or nitrosoureas) before study enrollment and recovered from the acute effects of therapy. * Males and females with reproductive potential: Must agree to use medically approved contraceptive precautions during the study and for 4 months following the last dose of study drug. * Females with childbearing potential: Must have had a negative urine or serum pregnancy test \<7 days before the first dose of study drug. * Have an estimated life expectancy of ≥16 weeks, in the opinion of the investigator. Exclusion Criteria: * Have received treatment within 30 days of the initial dose of study drug with an experimental agent for non-cancer indications that has not received regulatory approval for any indication. * Have one or more serious preexisting medical conditions that, in the opinion of the investigator, would preclude participation in this study. * Have an uncontrolled infection. * Females who are pregnant or breastfeeding. * Have known positive test results for human immunodeficiency virus (HIV), hepatitis B\*, or hepatitis C antibodies (HCAb). \* Have evidence of or test positive for hepatitis B. A positive test for hepatitis B is defined as: 1. positive for hepatitis B surface antigen (HBsAg+). OR 2. positive for anti-hepatitis B core antibody and positive for hepatitis B deoxyribonucleic acid (HBV DNA). OR 3. positive for anti-hepatitis B surface antibody (HBsAb+) and positive for hepatitis B deoxyribonucleic acid (HBV DNA). * Have ≥ Grade 2 peripheral neuropathy or any grade with pain as assessed using the Common Terminology Criteria for Adverse Events, version 4.03 (CTCAE v 4.03). * Have previously received an allogenic hematopoietic stem cell transplant. * Have previously received treatment with an experimental agent that targets B-cell activating factor (BAFF). * Have a corrected QT (QTc) interval \>470 msec on their baseline electrocardiogram (ECG). * Have interstitial pneumonitis (interstitial pneumonia) or pulmonary fibrosis manifested as opacity on chest X-ray or computed tomography (CT) scan. * Have had another active malignancy within the past 5 years.